Chemotherapy-induced nausea and vomiting is the most dreaded effect of chemotherapy. These side effects associated with chemotherapy can greatly affect the quality of life of the patient. According to medical sources, around 70% to 80% of cancer patients going through chemotherapy experience nausea and vomiting as major side effects. Players in the global chemotherapy-induced nausea and vomiting (CINV) drugs market are involved in intensive research and development activities to offer cancer patients drugs that help manage CINV better.
Browse Full Market Research Report on CINV Existing and Pipeline Drugs Market: http://www.transparencymarketresearch.com/cinv-market.html
Existing Drugs for CINV and Impact of Patent Expiry
Some of the major drugs in the global chemotherapy-induced nausea and vomiting (CINV) drugs market are Aloxi (palonosetron), Akynzeo (netupitant-palonosetron FDC), Emend (aprepitant), Kytril Generic (granisetron), and Zofran Generic (ondansetron).
Patents for key drugs such as Aloxi and Emend are going to expire in 2015. As a result, many manufacturers are expected to enter the industry with generic versions of these two brands and these cheaper versions will be sold for a price 80% lower than the branded drugs. This is expected to suppress the growth of the overall chemotherapy induced nausea and vomiting (CINV) drugs market.
According to a market research firm, Transparency Market Research (TMR), the global chemotherapy-induced nausea and vomiting (CINV) drugs market will expand at a moderate CAGR of 5.7% during the forecast period of 2014 to 2020. In 2013, the global CINV drugs market was worth US$1.28 billion and by 2020, the market is expected to be worth US$1.88 billion.
Major Pipeline Drugs for CINV and Other Emerging Drugs
There are several drugs in the global chemotherapy induced nausea and vomiting (CINV) drugs market to manage the condition. However, these side effects continue to be a major concern for oncologists and patients. Several companies in the global chemotherapy induced nausea and vomiting drugs market are striving to develop novel and more effective therapeutic solutions to manage CINV. Some of these companies are Heron Therapeutics, Helsinn Holding, and Tesaro.
Two key drugs to treat CINV that are currently in the pipeline are Rolapitant and SUSTOL (granisetron injection extended release). Rolapitant is a new oral drug that has a long plasma half-life. Currently, it is undergoing review by the FDA. In many studies, rolapitant regimen demonstrated statistically superior complete response rates as compared to granisetron control during the delayed phase. Other emerging new agents from the most recent trials include netupitant/palonosetron (NEPA).
Browse Press Release on CINV Existing and Pipeline Drugs Market: http://www.transparencymarketresearch.com/pressrelease/cinv-market.htm
In addition to this, there are studies that are evaluating the benefits of other substances such as ginger and olanzapine to prevent CINV. According to an Oxford Journal (Annals of Oncology), presently, studies exploring the optimal use of antiemetics in situations where high-dose chemotherapy is administered have been lacking. However, the evidence in favor of NK1RA (neurokinin-1 receptor antagonist) is accumulating.
More research is required to better understand nausea related to CINV in order to optimize the combinations and dosage of the existing or emerging drugs in chemotherapy situations.